-+ 0.00%
-+ 0.00%
-+ 0.00%

UBAMATAMAB (MUC16XCD3) SHOWS A HIGH RATE OF DURABLE RESPONSES IN INITIAL STUDY OF PATIENTS WITH ADVANCED LOW-GRADE SEROUS OVARIAN CANCER (LGSOC)

Reuters·10/01/2026 15:36:03